LP64672-6Natalizumab AbActive

Description

LP64672-6   Natalizumab Ab
Drug therapy for MS - loses effectiveness when patients develop antibodies to the drug. Detecting the antibodies early allows healthcare providers the opportunity to prescribe alternative therapy and avoid the cost associated with failed therapy. Source: Regenstrief Institute

Basic Part Properties

Name

Natalizumab Ab

Type

Component

Created On

2007-07-17

LOINC FHIR^® API Example - CodeSystem Request Get Info

Language Variants Get Info

zh-CNChinese (China)

那他珠单抗抗体
Synonyms: Natalizumab Ab;Natalizumab 抗体;那他珠单抗 Ab

LOINC Copyright

Copyright © 2022 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2022, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.